MedTrace Logo

Efficacy and Safety Trial With S 44819 After Recent Ischemic Cerebral Event

NCT02877615 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 585

Last updated 2020-03-11

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of S 44819 in enhancing functional recovery after an ischemic stroke.

Conditions

  • Post Stroke Recovery

Interventions

DRUG

S 44819 150 mg twice a day

One sachet of S 44819 150 mg and one sachet of placebo twice a day

DRUG

S 44819 300 mg twice a day

Two sachets of S 44819 150 mg twice a day

DRUG

Placebo

Two sachets of placebo twice a day

Sponsors & Collaborators

  • ADIR, a Servier Group company

    collaborator INDUSTRY

  • Institut de Recherches Internationales Servier

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-19
Primary Completion
2019-03-10
Completion
2019-03-10

Countries

  • Australia
  • Belgium
  • Brazil
  • Canada
  • Czechia
  • France
  • Germany
  • Hungary
  • Italy
  • Netherlands
  • Poland
  • South Korea
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02877615 on ClinicalTrials.gov